Analgesic Ketamine for Battlefield Use

Description

{"description":" The purpose of this RFI is to address the OPMED WPAC PMO’s requirement for Tactical Combat Casualty Care (TCCC) solutions for acute severe pain from battlefield injuries. The OPMED WPAC PMO is conducting market research to determine the feasibility to collaborate with industry to develop, manufacturer, and receive U.S. Food and Drug Administration (FDA) approval of an analgesic ketamine product for procurement. All ketamine products for any route of administration will be considered , for example: autoinjectors, oral capsules, pumps, topical creams and patches, etc. OPMED WPAC PMO plans to release a request for proposals for the analgesic ketamine product in Fiscal Year 2026. \n\n Please see list of attachments for other instructions. \n"} Solicitation Number: HT9427-26-RFI-701 Type: Sources Sought Base Type: Sources Sought Response Deadline: 2026-01-12T16:00:00-05:00 Office Address: FORT DETRICK, MD Place of Performance: Maryland, 21702 POC: Jeanette Collins, jeanette.m.collins4.civ@health.mil POC: Shannon Lertora, shannon.p.lertora.civ@health.mil {"description":" The purpose of this RFI is to address the OPMED WPAC PMO’s requirement for Tactical Combat Casualty Care (TCCC) solutions for acute severe pain from battlefield injuries. The OPMED WPAC PMO is conducting market research to determine the feasibility to collaborate with industry to develop, manufacturer, and receive U.S. Food and Drug Administration (FDA) approval of an analgesic ketamine product for procurement. All ketamine products for any route of administration will be considered , for example: autoinjectors, oral capsules, pumps, topical creams and patches, etc. OPMED WPAC PMO plans to release a request for proposals for the analgesic ketamine product in Fiscal Year 2026. \n\n Please see list of attachments for other instructions. \n"}